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This summary brings the most important information and
recommendations from the original full text ESC guidelines.
For the detailed information see the original document [1].
The level of evidence and the strength of recommendation
of particular treatment options were weighed and graded
according to pre-defined scales, as outlined in Tables A and B.2. Definition and terminology
Heart failure can be defined as an abnormality of cardiac
structure or function leading to failure of the heart to deliver
oxygen at a rate commensurate with the requirements of the
metabolizing tissues, despite normal filling pressures (or only
at the expense of increased filling pressures). For the pur-
poses of these guidelines, HF is defined, clinically, as a
syndrome in which patients have typical symptoms (e.g.
breathlessness, ankle swelling, and fatigue) and signs (e.g.
elevated jugular venous pressure, pulmonary crackles, and
displaced apex beat) resulting from an abnormality of cardiacstructure or function. Demonstration of an underlying car-
diac cause is central to the diagnosis of HF. This is usually
myocardial disease causing systolic ventricular dysfunction.
However, abnormalities of ventricular diastolic function or of
the valves, pericardium, endocardium, heart rhythm, and
conduction can also cause HF.
The main terminology used to describe HF is historical and
is based on measurement of LV ejection fraction (EF). The major
trials in patients with HF and a reduced EF (HF-REF), or ‘systolic
HF’, mainly enroled patients with an EFr35%, and it is only in
these patients that effective therapies have been demonstrated
to date. Other, more recent, trials enroled patients with HF and
an EF440–45% and no other causal cardiac abnormality. Some
of these patients did not have an entirely normal EF (generally
considered to be450%) but also did not have a major reduction
in systolic function either. Because of this, the term HF with
‘preserved’ EF (HF-PEF) was created to describe these patients.
Most have evidence of diastolic dysfunction, which is generally
accepted as the likely cause of HF in these patients (hence the
term ‘diastolic HF’). Patients with an EF in the range 35–50%
therefore represent a ‘grey area’ and most probably have
primarily mild systolic dysfunction.
Table B – Levels of evidence.
Level of evidence A Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C Consensus of opinion of the experts and/or small studies, retrospective studies, registries.
Table A – Classes of recommendations.
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‘chronic HF’. A treated patient with symptoms and signs, which
have remained generally unchanged for at least a month, is
said to be ‘stable’. If chronic stable HF deteriorates, the patient
may be described as ‘decompensated’ and this may happen
suddenly, i.e. ‘acutely’, usually leading to hospital admission, an
event of considerable prognostic importance. New (‘de novo’)
HF may present acutely, for example as a consequence of acute
myocardial infarction or in a subacute (gradual) fashion, for
example in a patient who has had asymptomatic cardiac
dysfunction, often for an indeterminate period, and may persist
or resolve (patients may become ‘compensated’).
The NYHA functional classification has been used to select
patients in almost all randomized treatment trials in HF and,
therefore, to describe which patients benefit from effective
therapies. Patients in NYHA class I have no symptoms
attributable to heart disease; those in NYHA classes II, III or
IV are sometimes said to have mild, moderate or severe
symptoms, respectively. It is important to note, however, that
symptom severity correlates poorly with ventricular function.
3. Epidemiology
Approximately 1–2% of the adult population in developed
countries has HF, with the prevalence rising to Z10% among
persons 70 years of age or older. There are many causes of HF,
and these vary in different parts of the world. At least half of the
patients with HF have a reduced EF (HF-REF). HF-REF is the best
understood type of HF in terms of pathophysiology andtreatment, and is the focus of these guidelines. Coronary artery
disease (CAD) is the cause of approximately two-thirds of cases
of systolic HF.
HF-PEF seems to have a different epidemiological and
aetiological profile from HF-REF. Patients with HF-PEF are older,
and more often female and obese than those with HF-REF. They
are less likely to have coronary heart disease and more likely to
have hypertension and atrial fibrillation (AF). Patients with HF-
PEF have a better prognosis than those with HF-REF.4. Diagnosis (Table 1)
4.1. Symptoms and signs
The diagnosis of HF can be difficult, especially in the early
stages. Symptoms like dyspnoe, fatigue and reduced exercise
tolerance are non-specific. Many of the signs of HF like
peripheral oedema and pulmonary crepitations result from
sodium and water retention, and are, therefore, also not
specific. Symptoms and signs may be particularly difficult
to identify and interpret in obese individuals, in the elderly,
and in patients with chronic lung disease. Symptoms and
signs are important in monitoring a patient’s response to
treatment and stability over time. Persistence of symptoms
despite treatment usually indicates the need for additional
therapy, and worsening of symptoms is a serious develop-
ment (placing the patient at risk of urgent hospital admission
and death) and merits prompt medical attention.
Table 2 – Common echocardiographic measures of left ventricular diastolic dysfunction in patients with heart failure.
Measurement Abnormality Clinical implications
e0 Decreased (o8 cm/s septal, o10 cm/s lateral, or o9 cm/s average) Delayed LV relaxation
E/e0 ratio High (415) High LV filling pressure
Low (o8) Normal LV filling pressure
Intermediate (8–15) Grey zone (additional parameters
necessary)
Mitral inflow E/A ratio ‘Restrictive’ (42) High LV filling pressure
Volume overload
‘Impaired relaxation’ (o1) Delayed LV relaxation
Normal LV filling pressure
Normal (1–2) Inconclusive (may be
‘pseudonormal’)
Mitral inflow during
Valsalva manoeuvre
Change of the ‘pseudonormal’ to the ‘impaired relaxation’ pattern
(with a decrease in E/A ratio Z0.5)
High LV filling pressure (unmasked
through Valsalva)
(A pulmA mitral)
duration
430 ms High LV filling pressure
A pulmA mitral¼Time difference between pulmonary vein flow Awave duration and mitral flow Awave duration; E/A¼ratio of early to
late diastolic mitral inflow waves; e0 ¼early diastolic velocity of mitral annulus; E/e0 ¼ratio of the mitral inflow E wave to the tissue Doppler e0
wave; HF¼heart failure; LV¼ left ventricular.
Table 1 – Diagnosis of heart failure.
The diagnosis of HF-REF requires three conditions to be satisfied:
1. Symptoms typical of HF
2. Signs typical of HFa
3. Reduced LVEF
The diagnosis of HF-PEF requires four conditions to be satisfied:
1. Symptoms typical of HF
2. Signs typical of HFa
3. Normal or only mildly reduced LVEF and LV not dilated
4. Relevant structural heart disease (LV hypertrophy/LA enlargement) and/or diastolic dysfunction
HF¼Heart failure; HF-PEF¼heart failure with ‘preserved’ ejection fraction; HF-REF¼heart failure and a reduced ejection fraction; LA¼ left
atrial; LV¼ left ventricular; LVEF¼ left ventricular ejection fraction.
a Signs may not be present in the early stages of HF (especially in HF-PEF) and in patients treated with diuretics.
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electrocardigraphy, laboratory tests
The echocardiogram and electrocardiogram (ECG) are the most
useful tests in patients with suspected HF. The echocardiogram
provides immediate information on chamber volumes, ventri-
cular systolic and diastolic function, wall thickness, and valve
function. This information is crucial in determining appropri-
ate treatment (e.g. an ACE inhibitor and beta-blocker for
systolic dysfunction or surgery for aortic stenosis).
To assess the left ventricular (LV) systolic (dys)function ejection
fraction (EF) is usually measured. The recommended echocardio-
graphic method for measurement of EF is the apical biplane
method of discs (the modified Simpson’s rule). The Teichholz and
Quinones methods of calculating EF from linear dimensions may
result in inaccuracies, particularly in patients with regional LV
dysfunction. The same is true for another technique for assessing
LV systolic function—fractional shortening. These and visual
assessment of EF (‘eye-balling’) are not recommended.
The Doppler echocardiographic indices are commonly used
to assess the LV diastolic (dys)function. This should include the
evaluation of both structural (LV hypertrophy, LA dilation) and
functional abnormalities (e.g. transmitral flow curve pattern—velocities E and A, E/A ratio). Tissue Doppler imaging (TDI)-
derived early diastolic myocardial velocities (e0), measured at the
mitral annulus, allow the assessment of myocardial relaxation. A
normal e0 (48 cm/s septal,410 cm/s lateral, or49 cm/s average,
measured using real-time pulsed TDI) is very unusual in a
patient with HF. The E/e0 ratio correlates with LV filling pressure.
Thus, echocardiographic evidence of LV diastolic dysfunction
may consist of a reduced e0 (e0 averageo9 cm/s) or an increased
E/e0 ratio (415), or a combination of these parameters. The
presence of at least two abnormal measurements and/or AF
increases the likelihood of the diagnosis of the HF-PEF (Table 2).
The ECG shows the heart rhythm and electrical conduction
abnormalities. These findings are also important for decisions
about treatment (e.g. rate control and anticoagulation for
atrial fibrillation, pacing for bradycardia, or CRT if the patient
has LBBB). The ECG may also show evidence of LV hypertro-
phy or Q waves, giving a possible clue to the aetiology of HF.
HF is very unlikely (likelihood o2%) in patients presenting
acutely and with a completely normal ECG.
Routine biochemical and haematological tests are important,
partly to determine whether renin–angiotensin–aldosterone
blockade can be initiated safely (renal function and potassium)
and to exclude anaemia and because they provide other, useful
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 5 – e 4 0 e29information. Other tests are generally only required if the
diagnosis remains unclear or if further evaluation of the under-
lying cause of the patient’s cardiac problem is indicated.
4.3. Natriuretic peptides
Measurement of the blood concentration of natriuretic peptides
could help to diagnose HF correctly. A normal natriuretic peptide
level in an untreated patient virtually excludes significant cardiac
disease and thus also HF. Multiple studies have examined the
threshold concentration that excludes HF for the two most
commonly used natriuretic peptides, B-type natriuretic peptide
(BNP) and N-terminal pro B-type natriuretic peptide (NT-proBNP).
The exclusion threshold differs for patients presenting with
acute onset or worsening of symptoms (e.g. to a hospital
emergency department) and those presenting with a more
gradual onset of symptoms. For patients presenting with acute
onset or worsening of symptoms, the optimal exclusion cut-off
point is 300 pg/mL for NT-proBNP and 100 pg/mL for BNP. For
patients presenting in a non-acute way, the optimum exclusion
cut-off point is 125 pg/mL for NT-proBNP and 35 pg/mL for BNP.
The sensitivity and specificity of BNP and NT-proBNP for the
diagnosis of HF are lower in non-acute patients.
4.4. Chest X-ray
A chest X-ray is of limited use in the diagnostic work-up of
patients with suspected HF. It is probably most useful in
identifying an alternative, pulmonary explanation for a
patient’s symptoms and signs. It may, however, show pul-
monary venous congestion or oedema in a patient with HF.
4.5. Other investigations
Cardiac magnetic resonance (CMR) is a non-invasive technique
that provides most of the anatomical and functional informa-
tion available from echocardiography, including evaluation of
ischaemia and viability, as well as additional assessments.
CMR is regarded as the gold standard with respect to accuracy
and reproducibility of volumes, mass, and wall motion.
Limitations include lack of availability, inability to image
patients with certain metallic implants, and cost.
Coronary angiography should be considered in patients with
angina pectoris or a history of cardiac arrest if the patient is
otherwise suitable for coronary revascularization. Angiogra-
phy should also be considered in patients with evidence of
reversible myocardial ischaemia on non-invasive testing,
especially if the EF is reduced, because coronary artery bypass
surgery may be beneficial.
With respect to the clinical setting other investigations could
provide useful information in patients with HF (e.g. stress
testing, ambulatory ECG monitoring, cardiac catheterization,
CT coronary angiography, endomyocardial biopsy, genetic test-
ing, positron emission tomography imaging and others).
4.5.1. Algorithm for the diagnosis of heart failure
An algorithm for the diagnosis of HF or LV dysfunction is
shown in Fig. 1.
In patients presenting to hospital as an emergency with
suspected HF and acute onset of symptoms, earlyechocardiography is recommended. If a natriuretic peptide
is measured, a high exclusion cut-off point should be used. In
patients presenting non-emergently in primary care, or to a
hospital outpatient clinic, with slow onset of symptoms and
signs suggestive of HF, an ECG and natriuretic peptide
measurement may be used as a means of identifying patients
who mostly need echocardiography.
An echocardiogram is indicated if the natriuretic peptide
level is above the exclusion threshold/ECG is abnormal. In
these patients, a lower exclusion natriuretic peptide cut-off
point should be used to prevent a ‘false-negative’diagnosis of
HF. Patients with a high pre-test likelihood of HF, such as
those with a history of myocardial infarction, may be referred
directly for echocardiography.5. Pharmacological treatment of heart failure
with reduced ejection fraction (systolic heart failure)
The goals of treatment in patients with established HF are to
relieve symptoms and signs, prevent hospital admission, and
improve survival. Fig. 2 shows a treatment strategy for the
use of drugs and devices in patients with HF-REF; the
recommendations for each treatment are summarized below.
Three neurohumoral antagonists – an ACE inhibitor [or
angiotensin receptor blocker (ARB)], a beta-blocker, and a
mineralocorticoid receptor antagonist (MRA) – are fundamen-
tally important in modifying the course of systolic HF and
should at least be considered in every patient (Table 3). They
are commonly used in conjunction with a diuretic given to
relieve the symptoms and signs of congestion.
The recommended doses of these disease-modifying med-
ications are given in Table 4. The key evidence supporting the
recommendations in this section is summarized in the
original full-text guidelines [1].
5.1. Angiotensin-converting enzyme inhibitors and
beta-blockers
The pivotal trials with beta-blockers were conducted in patients
with continuing symptoms and a persistently low EF, despite
treatment with an ACE inhibitor and, in most cases, a diuretic.
Despite this, there is consensus that these treatments are
complementary and that a beta-blocker and an ACE inhibitor
should both be started as soon as possible after diagnosis of HF-
REF. This is in part because ACE inhibitors have a modest effect
on LV remodelling whereas beta-blockers often lead to a sub-
stantial improvement in EF. Furthermore, beta-blockers are anti-
ischaemic, are probably more effective in reducing the risk of
sudden cardiac death, and lead to a striking and early reduction
in overall mortality.
ACE inhibitors occasionally causeworsening of renal function,
hyperkalemia, symptomatic hypotension, cough, and, rarely,
angioedema. An ACE inhibitor should only be used in patients
with adequate renal function (creatinine r221 mmol/L or
eGFRZ30mL/min/1.73m2) and a normal serum potassium level.
Three key trials with beta-blockers bisoprolol, carvedilol,
or metoprolol succinate CR/XL showed that beta-blocker
treatment reduced mortality (RRR about 34% in each trial)
and HF hospitalization (RRR 28–36%) within 1 year of starting
Fig. 1 – Diagnostic flowchart for patients with suspected heart failure—showing alternative ‘echocardiography first’ (blue) or
‘natriuretic peptide first’ (red) approaches. nIn the acute setting, MR-proANP may also be used (cut-off point 120 pmol/L, i.e.
o120 pmol/L¼heart failure unlikely). BNP¼B-type natriuretic peptide; ECG¼electrocardiogram; HF¼heart failure;
MR-proANP¼mid-regional pro atrial natriuretic peptide; NT-proBNP¼N-terminal pro B-type natriuretic peptide. (a) Exclusion
cut-off points for natriuretic peptides are chosen to minimize the false-negative rate while reducing unnecessary referrals for
echocardiography. (b) Other causes of elevated natriuretic peptide levels in the acute setting are an acute coronary syndrome,
atrial or ventricular arrhythmias, pulmonary embolism, and severe chronic obstructive pulmonary disease with elevated
right heart pressures, renal failure, and sepsis. Other causes of an elevated natriuretic level in the non-acute setting are: old
age (475 years), atrial arrhythmias, left ventricular hypertrophy, chronic obstructive pulmonary disease, and chronic kidney
disease. (c) Treatment may reduce natriuretic peptide concentration, and natriuretic peptide concentrations may not be
markedly elevated in patients with HF-PEF. (For interpretation of references to colour in this figure legend, the reader is
referred to the web version of this article.)
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with conventional treatment, including an ACE inhibitor.
Beta-blockers should be initiated in stable patients, and used
only with caution in recently decompensated patients. Conti-
nuation of beta-blocker treatment during an episode of decom-
pensation has been shown to be safe, although dose reduction
may be necessary. Temporary discontinuation is advised in
shocked or severely hypoperfused patients. Re-institution of
treatment should be attempted before hospital discharge.
5.2. Mineralocorticoid/aldosterone receptor antagonists
(MRAs)
Spironolactone and eplerenone block receptors bind aldos-
terone and other corticosteroids. The benefits of MRAsprobably extend to all patients with systolic HF, particularly
as the results of two RCTs in chronic HF (RALES II with
spironolactone and EMPHASIS-HF with eplerenone) are sup-
ported by the results of an additional RCT in patients with
acute myocardial infarction (EPHESUS with eplerenone).
Spironolactone and eplerenone can cause hyperkalaemia
and worsening renal function, which were uncommon in the
RCTs, but may occur more frequently in ordinary clinical
practice, especially in the elderly. Both should only be used in
patients with adequate renal function and a normal serum
potassium concentration; if either is used, serial monitoring
of serum electrolytes and renal function is mandatory.
Spironolactone can also cause breast discomfort and enlarge-
ment in men (10% compared with 1% on placebo); this side
effect is infrequent with eplerenone.
Fig. 2 – Treatment options for patients with chronic symptomatic systolic heart failure (NYHA functional class II–IV).
ACE¼angiotensin-converting enzyme; ARB¼angiotensin receptor blocker; CRT-D¼cardiac resynchronization
therapyþdefibrillator; CRT-P¼cardiac resynchronization therapyþpacemaker; H-ISDN¼hydralazine and isosorbide dinitrate;
HR¼heart rate; ICD¼ implantable cardioverter-defibrillator; LBBB¼ left bundle branch block; LVAD¼ left ventricular assist device;
LVEF¼ left ventricular ejection fraction; MR antagonist¼mineralocorticoid receptor antagonist; NYHA¼New York Heart
Association. (a) Diuretics may be used as needed to relieve the signs and symptoms of congestion but they have not been shown
to reduce hospitalization or death. (b) Should be titrated to evidence-based dose or maximum tolerated dose below the evidence-
based dose. (c) Asymptomatic patientswith an LVEFr35% and a history of myocardial infarction should be considered for an ICD.
(d) If mineralocorticoid receptor antagonist not tolerated, an ARBmay be added to an ACE inhibitor as an alternative. (e) European
Medicines Agency has approved ivabradine for use in patients with a heart rate Z75 b.p.m. May also be considered in patients
with a contraindication to a beta-blocker or beta-blocker intolerance. (f) Indication differs according to heart rhythm, NYHA class,
QRS duration, QRS morphology and LVEF. (g) Not indicated in NYHA class IV. (h) Digoxin may be used earlier to control the
ventricular rate in patients with atrial fibrillation—usually in conjunction with a beta-blocker. (i) The combination of hydralazine
and isosorbide dinitrate may also be considered earlier in patients unable to tolerate an ACE inhibitor or an ARB.
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Table 4 – Evidence-based doses of disease-modifying
drugs used in key randomized trials in heart failure (or
after myocardial infarction).
Starting dose
(mg)
Target dose
(mg)
ACE inhibitor
Captopril 6.25 t.i.d. 50 t.i.d.
Enalapril 2.5 b.i.d. 10–20 b.i.d.
Lisinopril 2.5–5.0 o.d. 20–35 o.d.
Ramipril 2.5 o.d. 5 b.i.d.
Trandolapril 0.5 o.d. 4 o.d
Beta-blocker
Bisoprolol 1.25 o.d. 10 o.d
Carvedilol 3.125 b.i.d. 25–50 b.i.d.
Metoprolol succinate (CR/
XL)
12.5/25 o.d. 200 o.d
Nebivolol 1.25 o.d. 10 o.d.
ARB
Candesartan 4 or 8 o.d. 32 o.d.
Valsartan 40 b.i.d. 160 b.i.d.
Losartan 50 o.d. 150 o.d.
MRA
Eplerenone 25 o.d. 50 o.d
Spironolactone 25 o.d. 25–50 o.d.
ACE¼Angiotensin-converting enzyme; ARB¼angiotensin receptor
blocker; b.i.d.¼bis in die (twice daily); MRA¼mineralocorticoid
receptor antagonist; o.d.¼omni die (once every day); t.i.d.¼ter in
die (three times daily).
Table 3 – Pharmacological treatments indicated in
potentially all patients with symptomatic (NYHA func-
tional class II–IV) systolic heart failure.
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with systolic heart failure
There are other drugs that are valuable in patients with systolic
HF. They have not, however, been shown clearly to reduce all-
cause mortality (or in the case of hydralazine and isosorbide
dinitrate this has only been clearly shown in African-Americans).
Most of these drugs have shown convincing benefits in terms of
symptom reduction, HF hospitalization, or both, and are useful
alternative or additional treatments in patients with HF—Table 5.
5.2.2. Angiotensin receptor blockers (ARBs)
ARBs remain recommended as an alternative in patients
intolerant of an ACE inhibitor. However, ARBs are no longer
the first choice recommendation in patients with HF and an
EFr40% who remain symptomatic despite optimal treatment
with an ACE inhibitor and beta-blocker. Two key placebo-
controlled RCTs (Val-HeFT and CHARM-Added) showed that
ARB treatment reduced the risk of HF hospitalization but not
all-cause hospitalization. Both trials also showed that ARBs
improve symptoms and quality of life.
5.3. Ivabradine
Ivabradine is a drug that inhibits the If channel in the sinus
node. Its only known pharmacological effect is to slow the
heart rate of patients in sinus rhythm.In the SHIFT trial with HF patients in NYHA functional class
II–IV, sinus rhythm with a rate of Z70 b.p.m., and an EFr35%
ivabradine decreased the rate of primary composite outcome of
cardiovascular death or HF hospitalization by 18% (Po0.0001); the
reduction in cardiovascular death (or all-cause death) was not
significant, but the RRR in HF hospitalization was 26%. Ivabradine
also improved LV function and quality of life. Additional safety
evidence for ivabradine comes from the BEAUTIFUL trial.5.4. Digoxin
In patients with symptomatic HF and AF, digoxin may be used
to slow a rapid ventricular rate, although other treatments
are preferred. Digoxin may also be used in patients in sinus
rhythm with symptomatic HF and an EFr40% based on the
evidence from the single large morbidity-mortality RCT DIG
which has been undertaken with digoxin in patients with
symptomatic HF and a low EF. This trial was performed
before beta-blockers were widely used for HF. Treatment with
digoxin did not alter all-cause mortality but did lead to an
RRR for hospital admission for worsening HF of 28% within
an average of 3 years of starting treatment. These findings are
supported by a meta-analysis of smaller trials suggesting that
digoxin can improve symptoms and prevent deterioration.5.4.1. Combination of hydralazine and isosorbide dinitrate
The addition of hydralazine–isosorbide dinitrate to conven-
tional therapy (ACE inhibitor, beta-blocker, and MRA) reduced
morbidity and mortality and improved symptoms in African-
Americans with HF. But the selected patient population
studied, relatively small RCT size, and early termination (for
Table 5 – Other treatments with less-certain benefits in patients with symptomatic (NYHA class II–IV) systolic heart
failure.
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 2 5 – e 4 0 e33mortality benefit) have left uncertainty about the real value of
this combination therapy, especially in nonblack patients.
5.4.2. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase
inhibitors (statins)
Although there is a wealth of robust evidence supporting the
value of statins in patients with atherosclerotic disease, most
trials excluded patients with HF. Two recent trials studied
statin treatment specifically in patients with chronic HF and
did not demonstrate convincing evidence of benefit. The
evidence does not therefore support the initiation of statins
in most patients with chronic HF.
5.5. Diuretics
The effects of diuretics on mortality and morbidity have not
been studied in patients with HF, unlike ACE inhibitors,
betablockers, and MRAs (and other treatments). However,
diuretics relieve dyspnoea and oedema and are recommendedfor this reason in patients with signs and symptoms of
congestion, irrespective of EF. Loop diuretics produce a more
intense and shorter diuresis than thiazides, which cause a
more gentle and prolonged diuresis. Thiazides may be less
effective in patients with reduced kidney function. Loop
diuretics are usually preferred to thiazides in HF-REF although
they act synergistically and the combination may be used
(usually on a temporary basis) to treat resistant oedema.
The aim of using diuretics is to achieve and maintain
euvolaemia (the patient’s ‘dry weight’) with the lowest achiev-
able dose. This means that the dose must be adjusted,
particularly after restoration of dry body weight, to avoid the
risk of dehydration leading to hypotension and renal dysfunc-
tion. This may reduce cardiac output in patients with HF-PEF
and often needlessly prevents the use of (or achievement of
the target dose of) other disease-modifying therapies such as
ACE inhibitors and MRAs in patients with HF-REF. Many
patients can be trained to self-adjust their diuretic dose, based
on monitoring of symptoms/signs of congestion and daily
Table 6 – Doses of diuretics commonly used to treat heart failure (with and without a preserved ejection fraction, chronic
and acute).
Diuretics Initial dose (mg) Usual daily dose (mg)
Loop diureticsa
Furosemide 20–40 40–240
Bumetanide 0.5–1.0 1–5
Torasemide 5–10 10–20
Thiazidesb
Bendroflumethiazide 2.5 2.5–10
Hydrochlorothiazide 25 12.5–100
Metolazone 2.5 2.5–10
Indapamidec 2.5 2.5–5
Potassium-sparing diureticsd
þACEi/ARB ACEi/ARB þACEi/ARB ACEi/ARB
Spironolactone/eplerenone 12.5–25 50 50 100–200
Amiloride 2.5 5 5–10 10–20
Triamterene 25 50 100 200
ACEi¼Angiotensin-converting enzyme inhibitor; ARB¼angiotensin receptor blocker.
a Oral or intravenous; dose might need to be adjusted according to volume status/weight; excessive doses may cause renal impairment and
ototoxicity.
b Do not use thiazides if estimated glomerular filtration rate o30 mL/min, except when prescribed synergistically with loop diuretics.
c Indapamide is a non-thiazide sulphonamide.
d A mineralocorticoid antagonist (MRA) i.e. spironolactone/eplerenone is always preferred. Amiloride and triamterene should not be combined
with an MRA.
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are shown in Table 6.6. Pharmacological treatment of heart failure
with ‘preserved’ ejection fraction (diastolic heart
failure)
No treatment has yet been shown, convincingly, to reduce
morbidity and mortality in patients with HF-PEF. Diuretics are
used to control sodium and water retention and relieve
breathlessness and oedema as in HF-REF. Adequate treat-
ment of hypertension and myocardial ischaemia is also
considered to be important, as is control of the ventricular
rate in patients with AF.
The few key mortality–morbidity trials finished to date
(CHARM-Preserved with candesartan, PEP-CHF with perindo-
pril, and I-Preserve with irbesartan) did not show any benefit
from the tested treatments.7. Non-surgical device treatment of heart
failure with reduced ejection fraction (systolic
heart failure)
This section discusses the use of ICDs and CRT. While no new
ICD RCT has completed since publication of the last guide-
lines in 2008, there have been several important RCTs using
CRT that have changed the recommendations.
7.1. Implantable cardioverter-defibrillator (ICD)
Approximately half of the deaths in patients with HF, espe-
cially in those with milder symptoms, occur suddenly and
unexpectedly, and most of these are related to ventricular
arrhythmias. Prevention of sudden death is therefore animportant goal in HF. While the key disease-modifying
neurohumoral antagonists mentioned earlier reduce the risk
of sudden death, they do not abort it. Specific antiarrhythmic
drugs do not decrease this risk (and may even increase it). For
this reason, ICDs have an important role to play in reducing
the risk of death from ventricular arrhythmias.
The implantation of an ICD for secondary prevention is
unambiguous. ICDs reduce mortality in survivors of cardiac
arrest and in patients with sustained symptomatic ventricu-
lar arrhythmias. Consequently, an ICD is recommended in
such patients, irrespective of EF, with good functional status,
a life expectancy of 41 year, and where the intent is to
increase survival.
For primary prevention an ICD is recommended in
patients with symptomatic HF (NYHA class II-III) and an
EFr35% despite Z3 months of treatment with optimal
pharmacological therapy, who are expected to survive for
41 year with good functional status, to reduce the risk of
sudden death. The ICD is indicated in patients with HF of
ischaemic aetiology, but more than 40 days after myocardial
infarction. There is less evidence in patients with non-
ischaemic HF—Table 7.7.2. Cardiac resynchronization therapy (CRT)
Two large RCTs (MADIT-CRT and RAFT trials) have shown that
CRT is of benefit in patients with mild symptoms (NYHA class
II) as well as in those who are more severely symptomatic
(COMPANION and CARE-HF trials). The benefits were additional
to those gained with conventional treatment, including a
diuretic, digoxin, an ACE inhibitor, a beta-blocker, a MRA, and
event. ICD. There is little doubt that patients expected to
survive with good functional status for41 year should receive
CRT if they are in sinus rhythm, their LVEF is low (r30%), QRS
duration is markedly prolonged (Z150ms), and an ECG shows
Table 7 – Recommendations for the use of implanted
cardioverter defibrillators in patients with heart failure.
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severity. There is less consensus about patients with right
bundle branch block or interventricular conduction delay and
those in AF (because most trials excluded these patients and
because a high ventricular rate will prevent resychronization).
Another area of debate is what to do in an HF-REF patient
without an indication for CRT who needs a conventional
pacemaker.
The recommendations for the use of CRT where the
evidence is strong are summarized in Table 8.8. Management of arrhythmias, particularly of
atrial fibrillation (AF)
AF is the most common arrhythmia in HF; it increases the
risk of thrombo-embolic complications (particularly stroke)
and may lead to worsening of symptoms. Whether AF is an
independent predictor of mortality is less certain, as is
whether it can cause systolic HF (‘tachycardiomyopathy’).
The management of atrial fibrillation is discussed in detail in
2010 ESC AF guidelines.
One of the most important problems is rate control in
patients with HF and persistent/permanent AF. An approach
to controlling the ventricular rate in patients with HF and AF
is shown in Fig. 3.9. Co-morbidities
Co-morbidities are important in patients with HF for four
main reasons. First, co-morbidities may affect the use oftreatments for HF (e.g. it may not be possible to use
renin–angiotensin system inhibitors is some patients with
renal dysfunction). Secondly, the drugs used to treat co-
morbidities may cause worsening of HF (e.g. NSAIDs given
for arthritis). Thirdly, the drugs used to treat HF and those
used to treat co-morbidities may also interact with one
another (e.g. beta-blockers and beta-agonists for chronic
obstructive pulmonary disease and asthma) and reduce
patient adherence. Lastly, most co-morbidities are associated
with worse clinical status and are predictors of poor prog-
nosis in HF (e.g. diabetes). This has led to some co-
morbidities themselves becoming targets for treatment (e.g.
anaemia).
The importance and specific management of the follow-
ing frequently occurring co-morbidities in HF patients
are described in the original full-text ESC guidelines: anae-
mia/iron deficiency, angina, cachexia, cancer, chronic
obstructive pulmonary disease/asthma, depression, diabetes,
erectile dysfunction, gout, hyperlipidaemia, hypertension,
obesity, prostatic hypertrophy, renal dysfunction and sleep
disorders [1].10. Acute heart failure
Acute heart failure (AHF) is the term used to describe the
rapid onset of, or change in, symptoms and signs of HF. It is a
life-threatening condition that requires immediate medical
attention and usually leads to urgent admission to hospital.
In most cases, AHF arises as a result of deterioration in
patients with a previous diagnosis of HF (either HF-REF or
HF-PEF), and all of the aspects of chronic management
described in these guidelines apply fully to these patients.
AHF may also be the first presentation of HF (‘de novo’ AHF).
AHF may be caused by an abnormality of any aspect of
cardiac function. In patients with pre-existing HF there is
often a clear precipitant or trigger (e.g. an arrhythmia or
discontinuation of diuretic therapy in a patient with HF-REF
and volume overload or severe hypertension in patients with
HF-PEF). The ‘acuteness’ may vary, with many patients
describing a period of days or even weeks of deterioration
(e.g. increasing breathlessness or oedema) but others devel-
oping HF within hours to minutes (e.g. in association with an
acute myocardial infarction). Patients may present with a
spectrum of conditions rating from life-threatening pulmon-
ary oedema or cardiogenic shock to a condition character-
ized, predominantly, by worsening peripheral oedema.
Diagnosis and treatment are usually carried out in paral-
lel, especially in patients who are particularly unwell, and
management must be initiated promptly. Close monitoring of
the patient’s vital functions is essential during the initial
evaluation and treatment and patients are best managed in
an intensive or coronary care unit. Although the immediate
goals of treatment are to improve symptoms and stabilize the
patient’s haemodynamic condition, longer term manage-
ment, including post-discharge care, is also particularly
important to prevent recurrences and improve prognosis in
HF-REF.
Initial assessment of patient with suspected acute heart
failure is listed in Fig. 4.
Table 8 – Recommendations for the use of CRTwhere the evidence is strong.
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Although not ‘evidence based’ in the sameway as treatments for
chronic HF, the key drugs are oxygen, diuretics, and vasodilators.
Opiates and inotropes are used more selectively, and mechanical
support of the circulation is required only rarely. Non-invasive
ventilation is used commonly in many centres, but invasive
ventilation is required in only a minority of patients.
Oxygen may be given to treat hypoxaemia (SpO2o90%).
Most patients with dyspnoea caused by pulmonary oedema
obtain rapid symptomatic relief from administration of an i.v.
diuretic. In patients with resistant peripheral oedema (and
ascites), a combination of a loop and a thiazide or thiazide-like
diuretic may be needed to achieve an adequate diuresis.
Opiates such as morphine may be useful in some patients
with acute pulmonary oedema as they reduce anxiety and
relieve distress associated with dyspnoea. Vasodilators reduce
preload and afterload and increase stroke volume (Table 9).
They are probably most useful in patients with hypertension
and should be avoided in patients with a systolic blood
pressureo110 mm Hg. Use of an inotrope such as dobutamine
(Table 10) should usually be reserved for patients with such
severe reduction in cardiac output that vital organ perfusion is
compromised. Such patients are almost always hypotensive
(‘shocked’). There is long-standing concern that they mayincrease mortality. Levosimendan can be used if it is felt
necessary to counteract the effect of a beta-blocker.
Systolic blood pressure, heart rhythm and rate, saturation
of peripheral oxygen (SpO2) using a pulse oximeter, and urine
output should be monitored on a regular and frequent basis
until the patient is stabilized.
After haemodynamic stabilization in patients with HF-REF
disease-modifying therapy (i.e. ACE inhibitor, beta-blocker,
and MRA) should be started as soon as possible (if the patient
is not already receiving these drugs) and the up-titration of
the dose should be started before discharge.
10.2. Non-pharmacological therapy
It is common to restrict sodium intake to o2 g/day and fluid
intake to o1.5–2.0 L/day (the latter in hyponatraemic patients),
especially during the initial management of an acute episode
of HF.
Non-invasive ventilation may be used as adjunctive therapy
to relieve symptoms in patients with pulmonary oedema and
severe respiratory distress or who fail to improve with pharma-
cological therapy. Contraindications include hypotension, vomit-
ing, possible pneumothorax, and depressed consciousness. The
primary indication for endotracheal intubation and invasive
ventilation is respiratory failure leading to hypoxaemia,
Fig. 3 – Recommendations for controlling the ventricular rate in patients with heart failure and persistent/permanent atrial
fibrillation and no evidence of acute decompensationn. nThrombo-embolism prophylaxis should also be considered in
parallel. yBeta-blocker treatment can cause worsening in acutely decompensated patients with HF-REF (see Section 10).
1Rate-limiting CCBs should be avoided in HF-REF. AV¼atrioventricular; CCB¼calcium-channel blocker; HF-PEF¼heart failure
with preserved ejection fraction; HF-REF¼heart failure with reduced ejection fraction.
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consciousness, and inability to maintain or protect the airway
are other reasons to consider intubation and ventilation.
Other possible non-pharmacological terapies in specific
situations include mechanical circulatory support (intra-aor-
tic baloon pump, ventricular assist device) and ultrafiltration.11. Coronary revascularization and surgical
therapy
11.1. Coronary revascularization
Surgical (and percutaneous) coronary revascularization is
indicated for the relief of angina pectoris in patients witheither HF-REF or HF-PEF, and surgical coronary revasculariza-
tion is indicated for ‘prognostic’ reasons in other patients
with severe CAD, particularly those with three-vessel disease
or significant left-main stenosis. The benefit–risk balance
for CABG in patients without angina/ischaemia or without
viable myocardium remains uncertain. Patients with 410%
of dysfunctional but viable LV myocardium may be more
likely to benefit from myocardial revascularization. Several
noninvasive techniques can be used to assess myocardial
viability.
The choice between percutaneous coronary intervention
and CABG should be made by the Heart Team, including a HF
specialist, and be based on the extent of CAD, expected
completeness of revascularization, associated valvular dis-
ease, and the presence of co-morbidities (Table 11).
Fig. 4 – Initial assessment of patient with suspected acute heart failure. ECG¼electrocardiogram; ETT¼endotracheal tube;
IABP¼intra-aortic balloon pump; NIV¼non-invasive ventilation; NP¼natriuretic peptide. (a) For example, respiratory distress,
confusion SpO2o90%, or PaO2o60mm Hg (8.0 kPa). (b) For example, ventricular tachycardia, third-degree atrioventricular block. (c)
Reduced peripheral and vital organ perfusion—patients often have cold skin and urine output r15ml/h and/or disturbance of
consciousness. (d) Percutaneous coronary revascularization (or thrombolysis) indicated if ST-segment elevation or new left bundle
branch block. (e) Vasodilators should be used with great caution, and surgery should be considered for certain acute mechanical
complications (e.g. inter-ventricular septal rupture, mitral valve papillary muscle rupture).
Table 9 – Intravenous vasodilators used to treat acute heart failure.
Vasodilator Dosing Main side effects Other
Nitroglycerine Start with10–20 mg/min, increase up to 200 mg/min Hypotension, headache Tolerance on continuous
use
Isosorbide
dinitrate
Start with 1 mg/h, increase up to 10 mg/h Hypotension, headache Tolerance on continuous
use
Nitroprusside Start with 0.3 mg/kg/min and increase up to 5 mg/kg/
min
Hypotension, isocyanate
toxicity
Light sensitive
Nesiritidea Bolus 2 mg/kgþinfusion 0.01 mg/kg/min Hypotension
a Not available in many European Society of Cardiology countries.
Table 10 – Drugs used to treat acute heart failure that are positive inotropes or vasopressors or both.
Bolus Infusion rate
Dobutamine No 2–20 mg/kg/min (bþ)
Dopamine No o3 mg/kg/min: renal effect (dþ)
3–5 mg/kg/min; inotropic (bþ)
45 mg/kg/min: (bþ), vasopressor (aþ)
Milrinone 25–75 mg/kg over 10–20 min 0.375–0.75 mg/kg/min
Enoximone 0.5–1.0 mg/kg over 5–10 min 5–20 mg/kg/min
Levosimedana 12 mg/kg over 10 min (optional)b 0.1 mg/kg/min, which can be decreased to 0.05 or increased
to 0.2 mg/kg/min
Norepinephrine No 0.2–1.0 mg/kg/min
Epinephrine Bolus: 1 mg can be given i.v. during resuscitation,
repeated every 3–5 min
0.05–0.5 mg/kg/min
a¼Alpha adrenoceptor; b¼beta adrenoceptor; d¼dopamine receptor.
a Also a vasodilator.
b Bolus not recommended in hypotensive patients (systolic blood pressure o90 mm Hg).
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Valvular heart disease may cause or aggravate HF. Therefore,
in patients with HF and signicifant aortic stenosis, aorticTable 11 – Recommendations for myocardial revascular-
ization in patients with chronic HF and systolic LV
dysfunction.
Table 12 – Heart transplantation: indications and contraindica
Patients to consider End-stage heart failure with severe symptoms
Motivated, well informed, and emotionally sta
Capable of complying with the intensive treat
Contraindications Active infection
Severe peripheral arterial or cerebrovascular d
Current alcohol or drug abuse
Treated cancer in previous 5 years
Unhealed peptic ulcer
Recent thrombo-embolism
Significant renal failure (e.g. creatinine cleara
Significant liver disease
Systemic disease with multiorgan involvemen
Other serious co-morbidity with poor prognos
Emotional instability or untreated mental illn
High, fixed pulmonary vascular resistence (4
HF¼Heart failure.regurgitation, or mitral regurgitation the surgical treatment
(valvuloplasty or valve replacement) is clearly indicated. The
indications are discussed in more detail in the original full-
text ESC guidelines [1].11.3. Heart transplantation
Heart transplantation is an accepted treatment for end-stage
HF. Although controlled trials have never been conducted,
there is consensus that transplantation – provided thattions.
, a poor prognosis, and no remaining alternative treatment options
ble
ment required post-operatively
isease
nce o50 mL/min)
t
is
ess
4–5 Wood Units and mean transpulmonary gradient 415 mm Hg)
Table 13 – Recommendations for surgical implantation of
LVADs in patients with systolic heart failure.
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survival, exercise capacity, quality of life, and return to work
compared with conventional treatment.
Apart from the shortage of donor hearts, the main chal-
lenges in transplantation are the consequences of the limited
effectiveness and complications of immunosuppressive ther-
apy in the long term (i.e. antibody-mediated rejection, infec-
tion, hypertension, renal failure, malignancy, and coronary
artery vasculopathy). The indications for and contraindica-
tions to heart transplantation are summarized in Table 12.
11.4. Mechanical circulatory support (MCS)
MCS is an umbrella term describing a number of different
technologies used to provide both short- and longer term
assistance in patients with either chronic HF or AHF. A variety
of terms have been used to describe the use of these technol-
ogies. The most experience is with MCS in end-stage HF,
initially as bridge to transplantation (BTT), but more recently
as so-called destination therapy (DT) in patients not eligible for
transplantation. For selected patients with end-stage HF, trans-
plantation remains the gold-standard treatment, with good
long-term survival. However, because of the increasing num-
bers of patients with end-stage HF, limited organ donation, and
technological advances, MCS with an LVassist device (LVAD) or
bi-ventricular assist device (BiVAD) is increasingly seen as an
alternative for some of these individuals.
It is recommended that such devices are only implanted
and managed at tertiary heart failure centres with appro-
priately trained, specialist HF physicians and surgeons. Ide-
ally these centres should also undertake transplantation.
Typically, patients with end-stage HF considered for MCS
are on continuous inotropic support (Table 13).
11.5. Exercise training and paliative care
11.5.1. Exercise training
Several systematic reviews and meta-analyses of small stu-
dies have shown that physical conditioning by exercisetraining improves exercise tolerance, health-related quality
of life, and HF hospitalization rates in patients with HF.
Therefore, it is recommended that regular aerobic exercise
is encouraged in patients with heart failure to improve
functional capacity and symptoms.11.5.2. Paliative care
HF has an unpredictable disease trajectory and it is often
difficult to identify a specific time point to consider palliative
care. At this point in a patient’s disease trajectory, the focus
should be on improvement in quality of life, control of
symptoms, early detection, and treatment of episodes of
deterioration, and on pursuing a holistic approach to patient
care, encompassing physical, psychological, social, and spiri-
tual well-being. Liaison between the specialist palliative care
service and the HF team and/or the primary care physician,
using a shared-care approach, is required in order to address
and coordinate the patients’ care optimally.
r e f e r e n c e
[1] ESC Guidelines for the diagnosis and treatment of acute and
chronic heart failure 2012. The Task Force for the Diagnosis
and Treatment of Acute and Chronic Heart Failure 2012 of the
European Society of Cardiology. Developed in collaboration
with the Heart Failure Association (HFA) of the ESC. Authors/
Task Force Members: John J.V. McMurray, Stamatis
Adamopoulos, Stefan D. Anker, Angelo Auricchio, Michael
Bo¨hm, Kenneth Dickstein, Volkmar Falk, Gerasimos
Filippatos, C ~andida Fonseca, Miguel Angel Gomez-Sanchez,
Tiny Jaarsma, Lars Kfber, Gregory Y.H. Lip, Aldo Pietro
Maggioni, Alexander Parkhomenko, Burkert M. Pieske, Bogdan
A. Popescu, Per K. Rfnnevik, Frans H. Rutten, Juerg Schwitter,
Petar Seferovic, Janina Stepinska, Pedro T. Trindade, Adriaan
A. Voors, Faiez Zannad, Andreas Zeiher. The original text is
available free on the ESC website: http://www.escardio.org/
guidelines-surveys/esc-guidelines/Pages/acute-chronic-
heart-failure.aspx and was originally published in European
Heart Journal 33 (2012) 1787–1847.
